Fresh EU Okay For Rubraca Boosts Clovis

 
• By Kevin Grogan

Rumors that Clovis is going to be an M&A target soon are on the rise after a second thumbs-up in Europe for the firm's PARP inhibitor Rubraca, this time as maintenance therapy for platinum-sensitive ovarian cancer in all-comers.

Station
Europe looks a welcoming market for Rubraca • Source: Shutterstock

More from New Products

More from Scrip